文献速递特殊人群用药

SGLT2抑制剂、GLP-1受体激动剂与DPP-4抑制剂在2型糖尿病患者新发低钠血症中的比较:多中心目标试验模拟

Use of SGLT2 Inhibitors, GLP‐1 Receptor Agonists, and DPP‐4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations
RSS 订阅 · Clinical Pharmacology & Therapeutics · 2026-10-27

本研究利用TriNetX全球协作网络155家医疗机构的电子健康记录,对2型糖尿病成人启动SGLT2抑制剂、GLP-1受体激动剂或DPP-4抑制剂进行多中心活性对照、新用户目标试验模拟,经1:1倾向评分匹配。结果显示,与DPP-4抑制剂相比,SGLT2抑制剂和GLP-1受体激动剂分别与低钠血症风险降低15%相关(HR 0.850和0.847),且在更严格钠阈值和临床相关亚组中一致。

要点

  • SGLT2抑制剂与GLP-1受体激动剂较DPP-4抑制剂降低新发低钠血症风险约15%。
  • 该较低风险在更严格血钠阈值及心衰、慢性肾病、高风险药物使用亚组中持续存在。
  • SGLT2抑制剂与GLP-1受体激动剂之间低钠血症风险 broadly 相当(HR 0.962)。

核心结论

  • 在2型糖尿病成人中,SGLT2抑制剂和GLP-1受体激动剂较DPP-4抑制剂与新发低钠血症风险降低相关。
  • 这些真实世界发现为SGLT2抑制剂和GLP-1受体激动剂的电解质安全性提供了 reassurance,补充其已确立的心肾获益。

研究设计与样本

  • 多中心活性对照、新用户目标试验模拟,使用TriNetX全球协作网络155家医疗机构的电子健康记录。
  • 每对比较经1:1倾向评分匹配,纳入既往365天无相应药物记录的2型糖尿病成人。
  • 每对比较匹配对数超过300,000对。

主要发现

  • SGLT2抑制剂 vs DPP-4抑制剂:低钠血症风险 HR 0.850(95% CI 0.842–0.858)。
  • GLP-1受体激动剂 vs DPP-4抑制剂:低钠血症风险 HR 0.847(95% CI 0.838–0.856)。
  • SGLT2抑制剂 vs GLP-1受体激动剂:HR 0.962(95% CI 0.952–0.971)。
  • 较低风险在更严格血钠阈值及心衰、慢性肾病、高风险药物使用亚组中持续存在。
  • 阳性与阴性对照结局与预期一致。

临床怎么用

  • 对于2型糖尿病合并低钠血症风险的患者,选择SGLT2抑制剂或GLP-1受体激动剂可能较DPP-4抑制剂更有利于电解质安全。
  • 在心衰、慢性肾病或使用高风险药物的患者中,SGLT2抑制剂和GLP-1受体激动剂的较低低钠血症风险仍可观察到。

局限性

  • 研究为观察性目标试验模拟,可能存在残余混杂。
  • 低钠血症定义基于ICD-10-CM编码或血清钠≤135 mmol/L,可能存在错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyponatremia poses risks in type 2 diabetes, yet comparative electrolyte safety across glucose-lowering therapies remains unclear. We evaluated the risk of incident hyponatremia associated with sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors in real-world practice. Using electronic health records from 155 healthcare organizations in the TriNetX Global Collaborative Network, we conducted multicenter active-comparator, new-user target trial emulations with 1:1 propensity score matching. For each pairwise comparison, adults with type 2 diabetes initiating either drug class, with no record of either class during the preceding 365 days, were included. The primary outcome was incident hyponatremia (ICD-10-CM E87.1 or serum sodium ≤ 135 mmol/L); sensitivity outcomes included diagnosis-only, laboratory-only, and stricter laboratory thresholds. Among more than 300,000 matched pairs per comparison, SGLT2 inhibitors and GLP-1 RAs were each associated with a 15% lower hazard of hyponatremia than DPP-4 inhibitors (hazard ratio [HR], 0.850; 95% confidence interval [CI], 0.842–0.858 and HR, 0.847; 95% CI: 0.838–0.856). The lower risk persisted at stricter sodium thresholds and across clinically relevant subgroups, including patients with heart failure, chronic kidney disease, or high-risk medications use. SGLT2 inhibitors and GLP-1 RAs were broadly comparable (HR, 0.962; 95% CI: 0.952–0.971). Positive and negative control outcomes were consistent with expectations. Overall, SGLT2 inhibitors and GLP-1 RAs were associated with a lower risk of incident hyponatremia than DPP-4 inhibitors. These real-world findings provide reassurance regarding the electrolyte safety of SGLT2 inhibitors and GLP-1 RAs, complementing their established cardiorenal benefits.

来源:Clinical Pharmacology & Therapeutics,查看原文。版权归原作者所有。

引用

  1. Clinical Pharmacology & Therapeutics:Use of SGLT2 Inhibitors, GLP‐1 Receptor Agonists, and DPP‐4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。